Patents Issued in January 14, 2016
  • Treatment Of HIV-1 Infection And AIDS
    Publication number: 20160008420
    Abstract: Provided herein are compositions and methods for the treatment of a patient having an HIV-1 infection and/or AIDS. More specifically this invention provides treatment of an HIV-1 infection and/or AIDS using small molecule compounds, such as inhibitors for the activation and/or activity of caspase-1. Inhibitors for the activation and/or activity of caspase-1 also prevent the cell death of CD4 T-cells in a population of CD4 T-cells comprising HIV-1 infected CD4 T-cells and uninfected CD4 T-cells. In addition, caspase-1 inhibitors inhibit inflammation, and pyroptosis.
    Type: Application
    Filed: September 4, 2015
    Publication date: January 14, 2016
    Inventors: Warner C. GREENE, Gilad Doitsh, Orlando Zepeda, Nicole Galloway
  • METHOD OF ALTERING VASCULAR PERMEABILITY AND USES THEREOF
    Publication number: 20160008421
    Abstract: Provided here are methods of modulating vascular permeability by changing the mechanical properties of extracellular matrices (ECM) and methods of treatment of diseases, conditions and symptoms related to vascular permeability such as pulmonary edema and acute respiratory distress syndrome (ARDS). The modulation can be increasing or decreasing vascular permeability. Vascular leakage can be normalized by increasing or decreasing ECM stiffness depending on the baseline mechanical properties of the tissue or organ. Vascular permeability is altered by changing the mechanical properties of ECM by administering a lysyl oxidase modulating (LOX) agent.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 14, 2016
    Inventors: Donald E. INGBER, Akiko MAMMOTO
  • COMPOSITIONS AND METHODS FOR CaMKII INHIBITORS AND USES THEREOF
    Publication number: 20160008422
    Abstract: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 14, 2016
    Inventors: K. Ulrich BAYER, Steve Coultrap
  • Occidiofungin, a unique antifungal glycopeptide produced by a strain of Burkholderia contaminans
    Publication number: 20160008423
    Abstract: The present invention is directed to novel antifungal glycopeptide compounds and salts thereof produced by a strain of Burkholderia contaminans useful for preventing or treating fungal infection or disease in animals and plants and the bacterial strain that produces the compounds.
    Type: Application
    Filed: July 22, 2015
    Publication date: January 14, 2016
    Applicant: Mississippi State University Research and Technology Corporation
    Inventors: Shien Lu, James L. Smith, Frank Austin, Ganyu Gu
  • APOE PEPTIDE DIMERS AND USES THEREOF
    Publication number: 20160008424
    Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.
    Type: Application
    Filed: March 20, 2015
    Publication date: January 14, 2016
    Inventors: Michael P. VITEK, Dale J. CHRISTENSEN
  • THERAPEUTIC AGENT FOR AMNIOTIC FLUID EMBOLISM
    Publication number: 20160008425
    Abstract: The present invention relates to a therapeutic agent for amniotic fluid embolism (AFE). Furthermore, the present invention relates to a therapeutic agent for AFE comprising a C1-inhibitor, particularly a human plasma-derived C1-inhibitor.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 14, 2016
    Applicant: CSL BEHRING GMBH
    Inventors: Naohiro KANAYAMA, Tomoaki IKEDA, Madoka FURUHASHI
  • NOVEL STIP1 POLYPEPTIDES AND USES THEREOF
    Publication number: 20160008426
    Abstract: The present invention is directed toward pharmaceutical compositions comprising an isolated polypeptide and a pharmaceutically acceptable carrier. The present invention also discloses an antibody or an antigen-binding portion thereof that bind to the isolated polypeptide.
    Type: Application
    Filed: July 30, 2015
    Publication date: January 14, 2016
    Inventors: Tzu-Hao Wang, Chia-Lung Tsai, Angel Chao
  • AFFINITY MATURED CRIg VARIANTS
    Publication number: 20160008427
    Abstract: The present invention concerns affinity matured CRIg variants. In particular, the invention concerns CRIg variants having increased binding affinity to C3b and retaining selective binding to C3b over C3.
    Type: Application
    Filed: April 20, 2015
    Publication date: January 14, 2016
    Applicant: GENENTECH, INC.
    Inventors: Sachdev S. SIDHU, Bing LI, Menno VAN LOOKEREN CAMPAGNE, Christian WIESMANN
  • COMPOSITIONS AND METHODS FOR ENHANCING CARDIAC FUNCTION
    Publication number: 20160008428
    Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.
    Type: Application
    Filed: March 7, 2014
    Publication date: January 14, 2016
    Applicant: University of Vermont and State Agriculture College
    Inventor: Jeffrey Spees
  • Methods for Achieving Therapeutically Effective Doses of anti-CD47 Agents
    Publication number: 20160008429
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Application
    Filed: February 26, 2014
    Publication date: January 14, 2016
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
  • Method to Increase Bioavailability of the Delta-Opioid Receptor for Management of Pain and Neuropsychiatric Disorders
    Publication number: 20160008430
    Abstract: Described herein is a method to induce surface trafficking of the delta-Opioid Receptor (DOR) and its applications, including, leveraging the antinociceptive potential of DOR agonists to treaty neurologic disorders and to be analgesics without the adverse consequences normally associated with chronic treatment by MOR agonists by inducing surface trafficking of the delta-Opioid Receptor (DOR) and screening compounds to identify additional targets for stimulated DOR delivery.
    Type: Application
    Filed: July 14, 2015
    Publication date: January 14, 2016
    Applicant: CARNEGIE MELLON UNIVERSITY, a Pennsylvania Non-Profit Corporation
    Inventors: Manojkumar A. Puthenveedu, Daniel J. Shiwarski, Amynah Pradhan
  • Tumor Therapy With Antitumor Agents In Combination With Sindbis Virus-Based Vectors
    Publication number: 20160008431
    Abstract: A method for treating malignant tumors with Sindbis viral based vectors in combination with antitumor agents and pharmaceutical formulations for use in such treatment.
    Type: Application
    Filed: July 13, 2015
    Publication date: January 14, 2016
    Inventors: Daniel Meruelo, Tomer Granot, Jen-Chieh Tseng
  • NEUREGULIN BASED METHODS FOR TREATING HEART FAILURE
    Publication number: 20160008432
    Abstract: The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.
    Type: Application
    Filed: June 22, 2015
    Publication date: January 14, 2016
    Inventor: Mingdong ZHOU
  • PEPTIDES AND COMPOSITIONS FOR TREATMENT OF JOINT DAMAGE
    Publication number: 20160008433
    Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Application
    Filed: March 7, 2014
    Publication date: January 14, 2016
    Applicant: NOVARTIS AG
    Inventors: Kristen JOHNSON, Jian SHI
  • STEM CELL FOR THERAPEUTIC USE WHICH IS DERIVED FROM HUMAN MONOCYTE, AND METHOD FOR INDUCING SAME
    Publication number: 20160008434
    Abstract: The present invention relates to stem cells obtained by culturing monocytes in the presence of (i) M-CSF and (ii) at least one member selected from the group consisting of ganglioside and water-soluble plant-derived extract, thereby dedifferentiating the monocytes; a therapeutic agent for treating damaged cells, tissues or organs; a cell drug agent; a method of producing stem cells, a culture medium for dedifferentiating monocytes; a dedifferentiation inducing agent; a cell drug kit; a kit for producing dedifferentiated cells; and a pharmaceutical composition.
    Type: Application
    Filed: September 24, 2015
    Publication date: January 14, 2016
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hisanobu HIRANO, Yasushi OHKUBO, Kenjiro SASAKI, Hironobu ISHIYAMA
  • COMPOSITION FOR PREVENTING OR TREATING B-CELL LYMPHOMA COMPRISING IL-21 EXPRESSING MESENCHYMAL STEM CELLS
    Publication number: 20160008435
    Abstract: Provided is a pharmaceutical composition for preventing or treating B-cell lymphoma including IL-21 expressing mesenchymal stem cells, and a treating method using the same.
    Type: Application
    Filed: March 27, 2015
    Publication date: January 14, 2016
    Inventors: Seok Goo CHO, Nayoun KIM
  • METHODS OF CONTROLLING PARASITIC WORMS IN ANIMALS
    Publication number: 20160008436
    Abstract: Disclosed herein are methods of controlling parasitic worms in herbivorous mammals and other species by orally administering an isolated antibody that specifically binds the interleukin-10 peptide or an interleukin-10 peptide. In the case of herbivorous mammals such as cattle, for example, administration of the anti-IL-10 antibodies increases weight gain and increases feed efficiency in the animals.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 14, 2016
    Inventors: Mark Eric Cook, Daniel Meilahn Schaefer, Mitchell Raymond Schaefer, Jordan Marshall Sand, Larry Smith
  • METHOD OF TREATMENT OF HYPOXIA INDUCIBLE FACTOR (HIF)-RELATED CONDITIONS
    Publication number: 20160008437
    Abstract: The present invention relates to methods of treatment of Hypoxia Inducible Factor (HIF)-related conditions, and in particular to methods of treatment of HIF-related conditions comprising the administration of a composition comprising transferrins.
    Type: Application
    Filed: June 30, 2015
    Publication date: January 14, 2016
    Applicant: Grifols Worldwide Operations Limited
    Inventors: David A. Ross, Ralph Christian Crumrine
  • Composition for Preventing or Treating Sepsis
    Publication number: 20160008438
    Abstract: Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of TNF, IL-1, and IL-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis.
    Type: Application
    Filed: May 10, 2013
    Publication date: January 14, 2016
    Applicants: KAEL-GEMVAX CO., LTD.
    Inventor: Sang Jae KIM
  • Method of Treating Metabolic Disorders Using PLA2G12A Polypeptides and PLA2G12A Mutant Polypeptides
    Publication number: 20160008439
    Abstract: Methods of treating or ameliorating metabolic diseases using a PLA2G12A polypeptide or PLA2G12A mutant polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes mellitus, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 14, 2016
    Inventors: Daniel C.H. LIN, Jinghong WANG, Yang LI
  • Use of CD83 in Combination Therapies
    Publication number: 20160008440
    Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.
    Type: Application
    Filed: October 1, 2015
    Publication date: January 14, 2016
    Inventors: Charles Nicolette, Stephen Brand, Zhen Zhong, Hao Wang, Jacqueline Arp, Siobhan Ramcharran, Miren Lorea Baroja
  • METHODS FOR TREATMENT OF INCONTINENCE ASSOCIATED WITH SEXUAL ACTIVITY
    Publication number: 20160008441
    Abstract: The invention provides compositions and methods for treating incontinence associated with sexual activity.
    Type: Application
    Filed: September 25, 2015
    Publication date: January 14, 2016
    Inventor: Mitchell F. Brin
  • TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY
    Publication number: 20160008442
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitor to an individual.
    Type: Application
    Filed: March 7, 2014
    Publication date: January 14, 2016
    Inventors: Rolf SPIRIG, Sylvia MIESCHER, Marc NOLTE, Claudia DUEHRKOP-SISEWITSCH, Robert RIEBEN
  • METHOD FOR TREATING A beta-AMYLOIDOSIS
    Publication number: 20160008443
    Abstract: The present invention relates to a composition comprising at least one mimotope of an epitope of alpha-synuclein for use in a method for preventing and/or treating ?-amyloidoses including Alzheimer's disease, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and Haemophilus influenzae protein D (protein D).
    Type: Application
    Filed: July 13, 2015
    Publication date: January 14, 2016
    Applicant: AFFIRIS AG
    Inventors: Markus MANDLER, Wolfgang Zauner, Frank Mattner, Walter Schmidt
  • XBP1, CD138, AND CS1 PEPTIDES
    Publication number: 20160008444
    Abstract: The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
    Type: Application
    Filed: June 29, 2015
    Publication date: January 14, 2016
    Inventors: Nikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
  • KNTC2 PEPTIDES AND VACCINES CONTAINING THE SAME
    Publication number: 20160008445
    Abstract: Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the KNTC2 gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both KNTC2-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 14, 2016
    Inventors: Takuya TSUNODA, Ryuji OSAWA, Sachiko YOSHIMURA, Tomohisa WATANABE
  • Autologous Tumor Lysate-loaded Dendritic Cell Vaccine for Treatment of Liver Cancer
    Publication number: 20160008446
    Abstract: The present disclosure provides compositions comprising mature dendritic cells loaded with autologous tumor cell lysates for the treatment of liver cancers, such as hepatocellular carcinoma. Hepatocellular carcinoma (HCC) is the fifth leading cancer and third leading cause of cancer-related mortality worldwide. Surgical resection and liver transplantation remain the mainstay of effective therapy for patients with early disease. However, a prevalent problem with HCC is the high likelihood of initial diagnosis at an advanced stage.
    Type: Application
    Filed: March 6, 2014
    Publication date: January 14, 2016
    Inventor: Spiros P. Hiotis
  • COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS
    Publication number: 20160008447
    Abstract: The present invention related to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. Specifically, the invention provides a method of identifying tumor specific neoantigens that alone or in combination with other tumor-associated peptides serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor responses.
    Type: Application
    Filed: July 8, 2015
    Publication date: January 14, 2016
    Inventors: Nir Hacohen, Catherine Ju-Ying Wu
  • RHOC-BASED IMMUNOTHERAPY
    Publication number: 20160008448
    Abstract: The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or peptides derived thereof or RhoC specific T-cells for treatment of metastatic cancer. Hence, the invention in one aspect relates to RhoC specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. Also the use of RhoC and immunogenic peptide fragments hereof in cancer treatment, diagnosis and prognosis is provided.
    Type: Application
    Filed: September 24, 2015
    Publication date: January 14, 2016
    Inventors: Mads Hald ANDERSEN, Per Thor STRATEN
  • CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE
    Publication number: 20160008449
    Abstract: The invention provides a method of protecting a bovine susceptible to Bibersteinia trehalosi, the method comprising administering to said bovine an effective amount of a vaccine comprising a Mannheimia haemolytica antigen, and further comprising one or more of Infectious Bovine Rhinotracheitis Virus, Bovine Viral Diarrhea Virus, Parainfluenza-3 Virus, and Bovine Respiratory Syncytial Virus.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 14, 2016
    Inventors: Terry Lynn Bowersock, Ryan N. Dunn, Randy Dean Leyh, Klaas Okkinga
  • COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE
    Publication number: 20160008450
    Abstract: The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.
    Type: Application
    Filed: July 14, 2015
    Publication date: January 14, 2016
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
  • NANOPARTICLE-BASED COMPOSITIONS
    Publication number: 20160008451
    Abstract: Provided herein are new compositions including an inactivated pathogen and one or more adjuvant-loaded polymeric nanoparticles, wherein the adjuvant-loaded nanoparticles are bound to the inactivated pathogen. These compositions are useful for preventing and/or treating diseases caused by the specific pathogens, especially when administered to a subject's mucosal membranes.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 14, 2016
    Inventors: Georg STARY, Aleksandar Filip RADOVIC-MORENO, Pamela A. BASTO, Michael N. STARNBACH, Robert S. LANGER, Omid C. FAROKHZAD, Ulrich Von ANDRIAN
  • Vault Compositions for Immunization
    Publication number: 20160008452
    Abstract: Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.
    Type: Application
    Filed: September 24, 2015
    Publication date: January 14, 2016
    Inventors: Valerie A. Kickhoefer, Leonard H. Rome, Kathleen A. Kelly, Cheryl Champion
  • MOLECULAR ANTIGEN ARRAY
    Publication number: 20160008453
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: November 14, 2014
    Publication date: January 14, 2016
    Applicant: CYTOS BIOTECHNOLOGY AG
    Inventors: WOLFGANG A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • COMPOSITIONS AND METHODS FOR TREATMENT OF MICROBIAL INFECTIONS
    Publication number: 20160008454
    Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
    Type: Application
    Filed: June 1, 2015
    Publication date: January 14, 2016
    Inventors: Jiri Pillich, John C. Balcarek
  • NOROVIRUS VACCINE FORMULATIONS
    Publication number: 20160008455
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Application
    Filed: July 10, 2015
    Publication date: January 14, 2016
    Inventors: Charles RICHARDSON, Thomas S. VEDVICK, Thomas R. FOUBERT, William T. TINO
  • FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
    Publication number: 20160008456
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Application
    Filed: September 29, 2015
    Publication date: January 14, 2016
    Inventors: Gale SMITH, Rick BRIGHT, Peter PUSHKO, Jinyou ZHANG, Kutub MAHMOOD
  • Inactivated Vaccine for Porcine Epidemic Diarrhea Virus (PEDV)
    Publication number: 20160008457
    Abstract: The present invention encompasses porcine epidemic diarrhea virus (PEDV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing inactivated PEDV. The invention also encompasses epitopes or immunogens which can be used to protect porcine animals against PEDV.
    Type: Application
    Filed: July 13, 2015
    Publication date: January 14, 2016
    Applicant: MERIAL, INC.
    Inventors: Srivishnupriya Anbalagan, Emily Collin, Benjamin Matthew Hause
  • CONDITIONALLY REPLICATION DEFICIENT HERPES VIRUS AND USE THEREOF IN VACCINES
    Publication number: 20160008458
    Abstract: The present invention is directed to a mutated recombinant herpesvirus, e.g., varicella zoster virus (VZV) and simian varicella virus strains or HSV-1 or HSV-2 strains, vaccines containing, and methods for the construction and use thereof to elicit protective immunity in susceptible individuals, wherein the particular herpesvirus is modified to render the virus replication deficient, i.e., the virus substantially or only replicates under defined conditions, by the incorporation of at least one destabilization domain in or fused to a gene essential for herpesvirus replication. The invention particularly relates to the use of the resultant conditionally replication defective herpesviruses, e.g., a mutated VZV strains in vaccine compositions in order to immunize individuals against herpesvirus infection, e.g.
    Type: Application
    Filed: September 11, 2013
    Publication date: January 14, 2016
    Inventors: Ravi MAHALINGAM, Donald GILDEN
  • IMMUNOGENIC POLYPEPTIDE SURFACE LAYER-EXPRESSING BIFIDOBACTERIUM
    Publication number: 20160008459
    Abstract: Provided is a gene for expressing an immunogenic polypeptide on the cell surface of a bifidobacterium, and the gene includes a gene encoding the immunogenic polypeptide, the immunogenic polypeptide includes a predetermined base domain and at least one antigenic peptide, and the at least one antigenic peptide is linked on any of the N-terminal side and the C-terminal side of the base domain. The gene for expressing an immunogenic polypeptide on a cell surface of a bifidobacterium of the present invention can further include a gene encoding a bifidobacterium-derived GNB/LNB substrate-binding membrane protein.
    Type: Application
    Filed: February 14, 2014
    Publication date: January 14, 2016
    Inventors: Toshiro SHIRAKAWA, Hak HOTTA, Takane KATAYAMA
  • VACCINATION STRATEGY
    Publication number: 20160008460
    Abstract: In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.
    Type: Application
    Filed: February 25, 2014
    Publication date: January 14, 2016
    Applicants: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN, TECHNISCHE UNIVERSITÄT MÜNCHEN, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GM
    Inventors: Percy Knolle, Li-Rung Huang, Mathias Heikenwälder, Ulrike Protzer
  • METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES
    Publication number: 20160008461
    Abstract: The invention relates to methods of generating a robust passive and an active immune response in a subject comprising administering a neutralizing antibody and a pathogen to the subject. The invention also relates to kits and pharmaceutical compositions useful in generating a robust passive and an active immune response in a subject.
    Type: Application
    Filed: August 2, 2014
    Publication date: January 14, 2016
    Inventors: William Rutter, Davide Corti
  • VETERINARY COMPOSITION AND METHOD OF IMPROVING LIVABILITY OF ANIMALS, PROMOTING LIVE WEIGHT GAIN IN MAMMALS AND BIRDS, ENHANCING THE EFFECTIVENESS OF IMMUNIZATION, AND PREVENTING AND/OR TREATING INFECTIOUS DISEASES (VARIANTS)
    Publication number: 20160008462
    Abstract: The present application provides a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to human insulin receptor and b) an activated-potentiated form of an antibody to human interferon gamma, which can be used for improving livability of animals, primarily, promoting live-weight gain and growth of mammals and birds (preferably food-producing animals and poultry), enhancing the effectiveness of immunization, preventing and/or treating a broad range of diseases (including infectious diseases of various etiology), and increasing livestock performance, reproduction and survival.
    Type: Application
    Filed: June 4, 2015
    Publication date: January 14, 2016
    Inventor: Oleg Iliich Epshtein
  • REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS
    Publication number: 20160008463
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
    Type: Application
    Filed: September 10, 2015
    Publication date: January 14, 2016
    Inventors: Michal EISENBACH-SCHWARTZ, Kuti BARUCH, Neta ROSENZWEIG
  • Methods Of Treatment Of Pterygium Using An Anti-VEGF Agent
    Publication number: 20160008464
    Abstract: Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.
    Type: Application
    Filed: September 22, 2015
    Publication date: January 14, 2016
    Inventor: Randal Tanh Hoang Pham
  • THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20160008465
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Application
    Filed: March 17, 2014
    Publication date: January 14, 2016
    Inventors: Ugur Sahin, Özlem Türeci
  • PARTICLE COMPOSITIONS AND METHODS RELATED THERETO
    Publication number: 20160008466
    Abstract: The disclosure relates to metal particles compositions and uses related thereto. In certain embodiments, the disclosure relates to metal particles such as iron particles and their application in imaging and treating cancer.
    Type: Application
    Filed: February 24, 2014
    Publication date: January 14, 2016
    Applicant: EMORY UNIVERSITY
    Inventor: Constantinos G. HADJIPANAYIS
  • METHOD FOR THE PRODUCTION OF SUB-MICROMETRIC PARTICLES AND THEIR THERANOSTIC USE IN ONCOLOGY WITH A SPECIFIC APPARATUS
    Publication number: 20160008467
    Abstract: The invention relates to a method for producing sub-micrometric particles, which comprises: mechanochemical treatment of homogeneous or heterogeneous magnetic materials until a mass which consists mostly of magnetic nanocrystal aggregates is obtained; selection of aggregates so that the nanocrystals have a Curie temperature within a predefined variation range; functionalization of the aggregates in order to obtain coating thereof with molecules of one or more of the following types of substances: substances for which the tumour cells have a particular metabolic avidity; substances having a biochemical affinity with the tumour cells; substances having an affinity with the acid microenvironment which surrounds the neoplastic cells.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 14, 2016
    Inventors: Paolo Matteazzi, Filippo Gherlinzoni, Michele Gottardi
  • DISEASE DETECTION AND TREATMENT THROUGH ACTIVATION OF COMPOUNDS USING EXTERNAL ENERGY
    Publication number: 20160008468
    Abstract: Described herein are compounds for the detection, diagnosis, and treatment of specific diseased tissues, including hyper-proliferative tissues such as tumors, and other tissue diseased with microbial and/or infectious species, using energy-activation methods. In particular, compounds sensitive to externally applied energy, including light and/or ultrasound; that also specifically accumulate in diseased target tissue, are provided.
    Type: Application
    Filed: November 1, 2013
    Publication date: January 14, 2016
    Inventor: Thomas J. Lewis
  • METHOD FOR PREPARING BIOMEDICAL METAL ALLOY MATERIAL WITH MULTI-DRUG DELIVERY SYSTEM
    Publication number: 20160008469
    Abstract: The present invention provides a method for preparing a biomedical metal alloy material with a multi-drug delivery system. A biomedical metal alloy material with a multi-drug delivery system according to the present invention is prepared by incorporating a therapeutic agent into a biodegradable material to prepare particles containing the therapeutic agent, treating the surface of the particles containing the therapeutic agent to have a charge opposite to the surface charge of a metal alloy material, and inducing an electrostatic interaction between the surface charges of the particles containing the therapeutic agent and the metal alloy material to immobilize the surface-treated particles containing the therapeutic agent on the surface of the metal alloy material.
    Type: Application
    Filed: December 18, 2012
    Publication date: January 14, 2016
    Applicant: Kwungpook National University Industry Academic Cooperation Foundation
    Inventor: Kwungpook National University Industry Academic Cooperation Foundation